Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Cited by (1,010)

Items 201–300 of 1,010

1. Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians
   Michael Allgäuer, Jan Budczies, Petros Christopoulos, Volker Endris, Amelie Lier, Eugen Rempel, Anna‐Lena Volckmar, Martina Kirchner, Moritz von Winterfeld, Jonas Leichsenring et al. · 2018 · Translational Lung Cancer Research
2. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
   Allen S. Ho, Angelica Ochoa, Gowtham Jayakumaran, Ahmet Zehir, Cristina Valero, Justin Tepe, Vladimir Makarov, Martin G. Dalin, Jie He, Mark Bailey et al. · 2019 · Journal of Clinical Investigation
3. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers
   Andrea Cercek, Walid Khaled Chatila, Rona D. Yaeger, Henry S. Walch, Gustavo dos Santos Fernandes, Asha R. Krishnan, Randze Lerie D. Palmaira, Anna Maio, Yelena M. Kemel, Preethi Srinivasan et al. · 2021 · JNCI Journal of the National Cancer Institute
4. Squamous cell lung cancer: Current landscape and future therapeutic options
   Sally C. M. Lau, Yuanwang Pan, Vamsidhar Velcheti, Kwok‐Kin Wong · 2022 · Cancer Cell
5. Cancer gene mutation frequencies for the U.S. population
   Gaurav Mendiratta, Eugene Ke, Meraj Aziz, David Liarakos, Melinda M. Tong, Edward C. Stites · 2021 · Nature Communications
6. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
   Linnéa La Fleur, Elin Falk-Sörqvist, Patrik Smeds, Anders Berglund, Magnus Sundström, Johanna SM Mattsson, Eva Brandén, Hirsh Koyi, Johan Isaksson, Hans Brunnström et al. · 2019 · Lung Cancer
7. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
   Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco, Victoria L. Robinson, Richard Ferraro, Sherri Z. Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim M. Abida et al. · 2022 · Nature Communications
8. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
   Aisner, Dara L., Sholl, Lynette M., Berry, Lynne D., Rossi, Michael R., Chen, Heidi, Fujimoto, Junya, Moreira, Andre L., Ramalingam, Suresh S., Villaruz, Liza C., Otterson, Gregory A. et al. · 2018 · Clinical Cancer Research
9. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
   Shaokun Shu, Hua‐Jun Wu, Jennifer Y. Ge, Rhamy Zeid, Isaac S. Harris, Bojana Jovanović, Katherine C. Murphy, Binbin Wang, Xintao Qiu, Jennifer E. Endress et al. · 2020 · Molecular Cell
10. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma
    Akimasa Hayashi, Jun Fan, Ruoyao Chen, Yu-Jui Ho, Alvin P. Makohon-Moore, Nicolas Lecomte, Yi Zhong, Jungeui Hong, Jinlong Huang, Hitomi Sakamoto et al. · 2020 · Nature Cancer
11. Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
    Alexander Edward Dela Cruz Drilon, Romel Somwar, Biju P. Mangatt, Henrik Edgren, Patrice Desmeules, Anja Ruusulehto, Roger S. Smith, Lukas Delasos, Morana Vojnic, Andrew J. Plodkowski et al. · 2018 · Cancer Discovery
12. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy
    Jin‐Ku Lee, Zhaoqi Liu, Jason K. Sa, Sang Hyun Shin, Jiguang Wang, Mykola Bordyuh, Hee Jin Cho, Oliver Elliott, Timothy Chu, Seung Won Choi et al. · 2018 · Nature Genetics
13. New clinical trial design in precision medicine: discovery, development and direction
    Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, Ke Liu, Zhan Wang, Yuan‐Sheng Zang · 2024 · Signal Transduction and Targeted Therapy
14. Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
    Clark, Travis A., Chung, Jon H., Kennedy, Mark, Hughes, Jason D., Chennagiri, Niru, Lieber, Daniel S., Fendler, Bernard, Young, Lauren, Zhao, Mandy, Coyne, Michael et al. · 2018 · The Journal of Molecular Diagnostics
15. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
    Andrea Forschner, Florian Battke, Dirk Hadaschik, Martin Schulze, Stephanie Weißgraeber, Tina Han, Maria Kopp, Maximilian Frick, Bernhard Daniel Klumpp, Nicola Tietze et al. · 2019 · Journal for ImmunoTherapy of Cancer
16. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
    Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian D. Rolfo, Alfredo Addeo · 2021 · Nature Reviews Clinical Oncology
17. Precision Oncology: The Road Ahead
    Daniela Senft, Mark D.M. Leiserson, Eytan Ruppin, Ze’ev A. Ronai · 2017 · Trends in Molecular Medicine
18. Library preparation for next generation sequencing: A review of automation strategies
    Jacob Friedrich Hess, Thomas Andreas Kohl, Michaela Kotrová, Kerstin Rönsch, Tobias Paprotka, Vanessa Mohr, Tobias Hutzenlaub, Monika Brüggemann, Roland Zengerle, Stefan Niemann et al. · 2020 · Biotechnology Advances
19. Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition
    Deshui Jia, Arnaud Augert, Dong Wook Kim, Emily Eastwood, Nan Wu, Ali H. Ibrahim, Kee‐Beom Kim, Colin T. Dunn, Smitha P.S. Pillai, Adi F. Gazdar et al. · 2018 · Cancer Discovery
20. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
    Justin Jee, Emily S. Lebow, Randy Yeh, Jeeban P. Das, Azadeh Namakydoust, Paul K. Paik, Jamie E. Chaft, Gowtham Jayakumaran, Angela Rose Brannon, Ryma Benayed et al. · 2022 · Nature Medicine
21. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism
    Patra, Krushna C., Kato, Yasutaka, Mizukami, Yusuke, Widholz, Sebastian, Boukhali, Myriam, Revenco, Iulia, Grossman, Elizabeth A., Ji, Fei, Sadreyev, Ruslan I., Liss, Andrew S. et al. · 2018 · Nature Cell Biology
22. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
    Jing Li, Weichao Wang, Yajia Zhang, Marcin P. Cieslik, Jipeng Guo, Mengyao Tan, Michael D. Green, Weimin Wang, Heng Lin, Wei Li et al. · 2020 · Journal of Clinical Investigation
23. Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers
    H. Courtney Hodges, Benjamin Z. Stanton, Kateřina Čermáková, Chiung-Ying Chang, Erik L. Miller, Jacob G. Kirkland, Wai Lim Ku, Václav Veverka, Keji Zhao, Gerald R. Crabtree · 2017 · Nature Structural & Molecular Biology
24. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma
    Maria Isabel Carlo, Semanti Mukherjee, Diana L. Mandelker, Joseph Vijai, Yelena M. Kemel, Liying Zhang, Andrea Knežević, Sujata Patil, Ozge Ceyhan‐Birsoy, Kuo-Cheng Huang et al. · 2018 · JAMA Oncology
25. Cell Biology of Canonical Wnt Signaling
    Lauren Veronica Albrecht, Nydia Tejeda‐Muñoz, Edward M. De Robertis · 2021 · Annual Review of Cell and Developmental Biology
26. Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
    Allison Betof Warner, Jessica S. Palmer, Alexander Noor Shoushtari, Debra A. Goldman, Katherine S. Panageas, Sara A. Hayes, Raazi Bajwa, Parisa Momtaz, Margaret K. Callahan, Jedd D. Wolchok et al. · 2020 · Journal of Clinical Oncology
27. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
    Vignesh Narasimhan, Josephine A. Wright, Michael Churchill, Tongtong Wang, Rachele Rosati, Tamsin R.M. Lannagan, Laura Vrbanac, Anne B. Richardson, Hiroki Kobayashi, Timothy Jay Price et al. · 2020 · Clinical Cancer Research
28. Integrated genomic profiling expands clinical options for patients with cancer
    Nike T. Beaubier, Martin Bontrager, Robert Huether, Catherine Igartua, Denise Lau, Robert W. Tell, Alexandria M. Bobe, Stephen J. Bush, Alan Lee Chang, Derick C. Hoskinson et al. · 2019 · Nature Biotechnology
29. Automated Real-World Data Integration Improves Cancer Outcome Prediction
    Jee, Justin, Fong, Christopher, Pichotta, Karl, Tran, Thinh Ngoc, Luthra, Anisha, Waters, Michele, Fu, Chenlian, Altoe, Mirella, Liu, Si-Yang, Maron, Steven B. et al. · 2024 · Nature
30. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
    Lee, Jessica K., Sivakumar, Smruthy, Schrock, Alexa B., Madison, Russell, Fabrizio, David, Gjoerup, Ole, Ross, Jeffrey S., Frampton, Garrett M., Napalkov, Pavel, Montesion, Meagan et al. · 2022 · npj Precision Oncology
31. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base
    Xiao‐Dong Jiao, Bao‐Dong Qin, Pu You, Jian Qiang Cai, Yuan‐Sheng Zang · 2018 · Lung Cancer
32. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer
    Eric Y. Stutheit-Zhao, Yaoqing Shen, Erin Pleasance, Katayoon Kasaian, Sreeja Leelakumari, Martin R. Jones, Pinaki Bose, Carolyn Ch’ng, Caralyn Reisle, Peter D. Eirew et al. · 2017 · Clinical Cancer Research
33. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms
    James P. Solomon, Jaclyn Frances Hechtman · 2019 · Cancer Research
34. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
    Peter M.K. Westcott, Nathan J. Sacks, Jason M. Schenkel, Zackery A. Ely, Olivia C. Ghirardelli Smith, Haley Hauck, Alex M. Jaeger, Daniel Zhang, Coralie M. Backlund, Mary Clare Beytagh et al. · 2021 · Nature Cancer
35. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
    Diana Merino Vega, Laura M. Yee, Lisa M. McShane, Paul Mickey Williams, L. Chen, Tomas Vilimas, David A. Fabrizio, Vincent Anthony Funari, Justin Y. Newberg, L.K. Bruce et al. · 2021 · Annals of Oncology
36. Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme
    Alona Sosinsky, John C. Ambrose, William C. H. Cross, Clare Turnbull, Shirley J. Henderson, J. Louise Jones, Angela D. Hamblin, Prabhu Arumugam, G. C. Chan, Daniel Chubb et al. · 2024 · Nature Medicine
37. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
    Miryam Müller, Thomas Graham Bird, Jean‐Charles Nault · 2020 · Journal of Hepatology
38. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia
    Ching‐Hon Pui, Kim E. Nichols, Jun J.J. Yang · 2018 · Nature Reviews Clinical Oncology
39. Next generation sequencing‐based gene panel tests for the management of solid tumors
    Masayuki Nagahashi, Yoshifumi Shimada, Hiroshi Ichikawa, Hitoshi Kameyama, Kazuaki Takabe, Shujiro Okuda, Toshifumi Wakai · 2018 · Cancer Science
40. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
    Angela Rose Brannon, Gowtham Jayakumaran, Monica S. Diosdado, Juber Patel, Разумова Анна Ивановна, Yu Hu, Fanli Meng, Mohammad Haque, Justyna Sadowska, Brian J. Murphy et al. · 2021 · Nature Communications
41. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
    Thomas Boerner, Esther N Drill, Linda M. Pak, Bastien Nguyen, Carlie Sigel, Alexandre Doussot, Paul J. Shin, Debra A. Goldman, Mithat Gönen, Peter J. Allen et al. · 2021 · Hepatology
42. Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors
    Elise M. Fiala, Gowtham Jayakumaran, Audrey Mauguen, Jennifer A. Kennedy, Nancy Bouvier, Yelena M. Kemel, Megan Harlan Fleischut, Anna Maio, Erin E. Salo‐Mullen, Margaret R. Sheehan et al. · 2021 · Nature Cancer
43. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
    Philip C. Mack, Kimberly C. Banks, Carin R. Espenschied, Rebekah A. Burich, Oliver A. Zill, Christine E. Lee, Jonathan Wesley Riess, Stefanie Mortimer, AmirAli H. Talasaz, Richard Burnham Lanman et al. · 2020 · Cancer
44. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA
    Erik N. Bergstrom, Jens Luebeck, Mia Petljak, Azhar Khandekar, Mark D. Barnes, Tongwu Zhang, Christopher D. Steele, Nischalan Pillay, Maria Teresa Landi, Vineet Bafna et al. · 2022 · Nature
45. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes
    Erin Pleasance, Emma Titmuss, Laura Williamson, Harwood Kwan, Luka Culibrk, Eric Y. Stutheit-Zhao, Katherine Dixon, Kevin Yijun Fan, Reanne Bowlby, Martin R. Jones et al. · 2020 · Nature Cancer
46. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
    Todd Cory Knepper, Meagan Montesion, Jeffery Scott Russell, Ethan S. Sokol, Garrett Michael Frampton, Vincent A. Miller, Lee A. Albacker, Howard L. McLeod, Zeynep Eroglu, Nikhil I. Khushalani et al. · 2019 · Clinical Cancer Research
47. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
    Susan Faye Dent, Javier Cortés, Young‐Hyuck Im, Veronique C Dieras, Nadia Harbeck, Ian E. Krop, Timothy Richard Wilson, N. Cui, Frauke Schimmöller, Jerry Y. Hsu et al. · 2020 · Annals of Oncology
48. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
    Jian Wang, hao-Ting sun, Q. Zeng, Xue-Jun Guo, Hui Wang, Huan Liu, Zhong-Yi Dong · 2019 · Scientific Reports
49. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis
    Kosuke Tanaka, Helena Alexandra Yu, Shaoyuan Yang, Song Han, S. Duygu Selçuklu, Kwanghee Kim, Shriram Ramani, Yogesh Tengarai Ganesan, Allison F. Moyer, Sonali Sinha et al. · 2021 · Cancer Cell
50. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
    Qing Li, Baishan Jiang, Jiaye Guo, Hong Shao, Isabella S. Del Priore, Qing Chang, Rei Kudo, Zhiqiang Li, Pedram Razavi, Bo Liu et al. · 2021 · Cancer Discovery
51. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma
    Guo Gord Zhu, Ryma Benayed, Caleb Ho, Kerry A. Mullaney, Purvil Sukhadia, Kelly Rios, Ryan Berry, Brian P. Rubin, Khédoudja Nafa, Lu Wang et al. · 2018 · Modern Pathology
52. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
    Khalil Choucair, Susan M. Morand, Laura Stanbery, Gerald M. Edelman, Lance D. Dworkin, John J. Nemunaitis · 2020 · Cancer Gene Therapy
53. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
    Variant Interpretation for Cancer Consortium, Wagner, Alex H., Walsh, Brian, Mayfield, Georgia, Tamborero, David, Sonkin, Dmitriy, Krysiak, Kilannin, Deu-Pons, Jordi, Duren, Ryan P., Gao, Jianjiong et al. · 2020 · Nature Genetics
54. HER2-targeted therapies beyond breast cancer — an update
    Jeesun Yoon, Do‐Youn Oh · 2024 · Nature Reviews Clinical Oncology
55. DNAJB1–PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma
    Edward R. Kastenhuber, Gadi Lalazar, Shauna Lee Houlihan, Darjus Felix Tschaharganeh, Timour Baslan, Chi-Chao Chen, David Requena, Sha Tian, Benedikt Bosbach, John Erby Wilkinson et al. · 2017 · Proceedings of the National Academy of Sciences
56. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
    Winifred M. Lo, Maria R. Parkhurst, Paul F. Robbins, Eric Tran, Yong‐Chen Lu, Lee Jia, Jared J. Gartner, Anna Pasetto, Drew C. Deniger, Parisa Malekzadeh et al. · 2019 · Cancer Immunology Research
57. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
    Piers A. Blombery, Ella R. Thompson, Tamia Nguyen, Richard W. Birkinshaw, Jianan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson et al. · 2020 · Blood
58. Molecular targets of tyrosine kinase inhibitors in thyroid cancer
    Poupak Fallahi, Silvia Martina Ferrari, Maria Rosaria Galdiero, Gilda Varricchi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Salvatore Benvenga, Alessandro Antonelli · 2020 · Seminars in Cancer Biology
59. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
    Qiang Li, Alexis W. Damish, Zoë Frazier, David Liu, Elizaveta Reznichenko, Atanas Kamburov, Andrew Bell, HuiYong Zhao, Emmet Jordan, Sizhi Paul Gao et al. · 2018 · Clinical Cancer Research
60. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Pedram Razavi, Maura N. Dickler, Payal Deepak Shah, Weiyi Toy, David N. Brown, Helen H. Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi et al. · 2020 · Nature Cancer
61. The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma
    Raul Caso, Francisco Sánchez-Vega, Kay See Tan, Brooke Mastrogiacomo, Jian Hua Zhou, Gregory D. Jones, Bastien Nguyen, Nikolaus D. Schultz, James G. Connolly, Whitney S. Brandt et al. · 2020 · Journal of Thoracic Oncology
62. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
    Walid Khaled Chatila, Jin K. Kim, Henry S. Walch, Michael R. Marco, Chin‐Tung Chen, Fan Hong Wu, Dana Mohamed Rashid Omer, Danny N. Khalil, Karuna Ganesh, Xuan Qu et al. · 2022 · Nature Medicine
63. Drugging KRAS: Current perspectives and state-of-art review
    Parikh, Kaushal, Banna, Giuseppe, Liu, Stephen V., Friedlaender, Alex, Desai, Aakash, Subbiah, Vivek, Addeo, Alfredo · 2022 · Journal of Hematology & Oncology
64. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
    Wolfgang Michael Brueckl, Joachim Hans Ficker, Gloria Zeitler · 2020 · BMC Cancer
65. Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
    Philip Jonsson, Andrew L. Lin, Robert J. Young, Natalie M. DiStefano, David Michael Hyman, Bob T. Li, Michael F. Berger, Ahmet Zehir, Marc Ladanyi, David B. Solit et al. · 2019 · Clinical Cancer Research
66. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
    Erin Frances Cobain, Yi‐Mi Wu, Pankaj Vats, Rashmi K Chugh, Francis Paul Worden, David Carl Smith, Scott M. Schuetze, Mark M. Zalupski, Vaibhav Sahai, Ajjai Shivaram Alva et al. · 2021 · JAMA Oncology
67. PD-L1 expression testing in non-small cell lung cancer
    Cristina Teixidó, Noelia Vilariño, Roxana Reyes, Noemı́ Reguart · 2018 · Therapeutic Advances in Medical Oncology
68. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
    Ezra Y. Rosen, Debra A. Goldman, Jaclyn Frances Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie G. Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon et al. · 2019 · Clinical Cancer Research
69. Argonaute integrated single-tube PCR system enables supersensitive detection of rare mutations
    Qian Liu, Xiang Guo, Guanhua Xun, Zhonglei Li, Yuesheng Chong, Litao Yang, Hongxia Wang, Fengchun Zhang, Shukun Luo, Li Cui et al. · 2021 · Nucleic Acids Research
70. Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy
    Roni Shouval, Ana Alarcon Tomas, Joshua Alexander Fein, Jessica R. Flynn, Ettai Markovits, Shimrit Mayer, Aishat Olaide Afuye, Anna Alperovich, Theodora Anagnostou, Michal Judith Besser et al. · 2021 · Journal of Clinical Oncology
71. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab
    Andrew L. Lin, Philip Jonsson, Viviane S. Tabar, Jonathan T. Yang, John J. Cuaron, K. Beal, Marc A. Cohen, Michael Andrew Postow, Marc K. Rosenblum, Jinru Shia et al. · 2018 · The Journal of Clinical Endocrinology & Metabolism
72. Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
    Ivo Buchhalter, Eugen Rempel, Volker Endris, Michael Allgäuer, Olaf Neumann, Anna‐Lena Volckmar, Martina Kirchner, Jonas Leichsenring, Amelie Lier, Moritz von Winterfeld et al. · 2018 · International Journal of Cancer
73. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
    B.T. Li, Filip Jankú, Birte Kristin Jung, C. Hou, Kiran Madwani, Ryan S. Alden, Pedram Razavi, Jorge Sergio Reis-Filho, Ronglai Shen, James M. Isbell et al. · 2019 · Annals of Oncology
74. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
    Man Keung, Yanyuan Wu, Jaydutt V. Vadgama · 2019 · Journal of Clinical Medicine
75. Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
    Sai‐Hong Ignatius Ou, Viola Weijia Zhu, Misako Nagasaka · 2020 · JTO Clinical and Research Reports
76. Metabolic Adaptations in Cancer Stem Cells
    Umesh Prasad Yadav, Tashvinder Singh, Pramit Kumar, Praveen Sharma, Harsimrat Kaur, Sadhana Sharma, Sandeep Singh, Santosh Kumar, Kapil Mehta · 2020 · Frontiers in Oncology
77. Mechanisms of Resistance to KRASG12C-Targeted Therapy
    Akhave, Neal S., Biter, Amadeo B., Hong, David S. · 2021 · Cancer Discovery
78. Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy
    Eugene J. Pietzak, Emily Craig Zabor, Aditya Bagrodia, Joshua Armenia, Wenhuo Hu, Ahmet Zehir, Samuel Aaron Funt, François Audenet, David A. Barron, Noelia Maamouri et al. · 2018 · European Urology
79. Role of liver biopsy in hepatocellular carcinoma
    Luca Di Tommaso, Marco Spadaccini, Matteo Donadon, Nicola Personeni, Abubaker Elamin, Alessio Aghemo, Ana Lleò · 2019 · World Journal of Gastroenterology
80. Applications and analysis of targeted genomic sequencing in cancer studies
    Findlay Bewicke‐Copley, Emil Arjun Kumar, Giuseppe Palladino, Koorosh Korfi, Jun Wang · 2019 · Computational and Structural Biotechnology Journal
81. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
    Zsofia Kinga Stadler, Anna Maio, Debyani Chakravarty, Yelena M. Kemel, Margaret R. Sheehan, Erin E. Salo‐Mullen, Kaitlyn A. Tkachuk, Christopher John Fong, Bastien Nguyen, Amanda Erakky et al. · 2021 · Journal of Clinical Oncology
82. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
    Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M. et al. · 2019 · Annals of Oncology
83. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer
    Francisco Sánchez-Vega, Jaclyn Frances Hechtman, Pau Castel, Geoffrey Yuyat Ku, Yaelle Tuvy, Helen H. Won, Christopher John Fong, Nancy Bouvier, Gouri J. Nanjangud, Joanne Soong et al. · 2018 · Cancer Discovery
84. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
    Biagio Ricciuti, Gonzalo Recondo, Liam Flinn Spurr, Yvonne Y. Li, Giuseppe Lamberti, Deepti Venkatraman, Renato Umeton, Andrew D. Cherniack, Mizuki Nishino, Lynette Marie Sholl et al. · 2020 · Clinical Cancer Research
85. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
    Simpson, Rebecca C., Shanahan, Erin R., Scolyer, Richard A., Long, Georgina V. · 2023 · Nature Reviews Clinical Oncology
86. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
    Zeid Kuzbari, Chaitanya Bandlamudi, Chey Loveday, A. Garrett, Miika M. Mehine, Angela Joy George, Helen Hanson, Katie M.G. Snape, Anju Kulkarni, Sophie Allen et al. · 2022 · Annals of Oncology
87. Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
    Yaeger, Rona, Mezzadra, Riccardo, Sinopoli, Jenna, Bian, Yu, Marasco, Michelangelo, Kaplun, Esther, Gao, Yijun, Zhao, HuiYong, Paula, Arnaud Da Cruz, Zhu, Yingjie et al. · 2023 · Cancer Discovery
88. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations
    José Maurício Mota, Ethan S. Barnett, Jones Trevor Nauseef, Bastien Nguyen, Konrad Hermann Stopsack, Andreas Georg Wibmer, Jessica R. Flynn, Glenn Heller, Daniel Costin Danila, Dana E. Rathkopf et al. · 2020 · JCO Precision Oncology
89. Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
    Smruthy Sivakumar, Jay A. Moore, Meagan Montesion, Radwa Raed Sharaf, Douglas I. Lin, Caterina I. Colón, Zoë Fleischmann, Ericka M. Ebot, Justin Y. Newberg, Jennifer M. Mills et al. · 2023 · Cancer Discovery
90. Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity
    Joanna Cyrta, Anke Augspach, Maria Rosaria De Filippo, Davide Prandi, Phillip Thienger, Matteo Benelli, Victoria Cooley, Rohan Bareja, David C. Wilkes, Sung-Suk Chae et al. · 2020 · Nature Communications
91. OncoTree: A Cancer Classification System for Precision Oncology
    Ritika Kundra, Hongxin Zhang, Robert Sheridan, Sahussapont Joseph Sirintrapun, Avery Wang, Angelica Ochoa, Manda Wilson, Benjamin E Gross, Yichao Sun, Ramyasree Madupuri et al. · 2021 · JCO Clinical Cancer Informatics
92. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours
    Johansson, Peter A., Brooks, Kelly, Newell, Felicity, Palmer, Jane M., Wilmott, James S., Pritchard, Antonia L., Broit, Natasa, Wood, Scott, Carlino, Matteo S., Leonard, Conrad et al. · 2020 · Nature Communications
93. Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
    Tara E. Soumerai, Mark T.A. Donoghue, Chaitanya Bandlamudi, Preethi Srinivasan, Matthew T. Chang, Dmitriy Zamarin, Karen Anne Cadoo, Rachel Nicole Grisham, Roisin Eilish O'Cearbhaill, William P. Tew et al. · 2018 · Clinical Cancer Research
94. Therapeutic landscape and future direction of metastatic colorectal cancer
    Hideaki Bando, Atsushi Ohtsu, Takayuki Yoshino · 2023 · Nature Reviews Gastroenterology & Hepatology
95. Molecular Diagnostics in Clinical Oncology
    Анна Петровна Соколенко, Евгений Наумович Имянитов · 2018 · Frontiers in Molecular Biosciences
96. Ten years of DICER1 mutations: Provenance, distribution, and associated phenotypes
    Leanne de Kock, Mona K. Wu, William David Foulkes · 2019 · Human Mutation
97. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
    Alexa Betzig Schrock, Viola Weijia Zhu, Wen-Son Hsieh, Russell William Madison, Ben Creelan, Jeffrey Silberberg, Dan Costin, Anjali Bharne, Ioana R. Bonta, Thangavijayan Bosemani et al. · 2018 · Journal of Thoracic Oncology
98. Systematic identification of mutations and copy number alterations associated with cancer patient prognosis
    Joan C. Smith, Jason M. Sheltzer · 2018 · eLife
99. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
    Takayuki Yoshino, G. Pentheroudakis, Saori Mishima, Michael James Overman, Kun‐Huei Yeh, Eishi Baba, Yoichi Naito, Fabien M. Calvo, Ajit Kumar Saxena, L.-T. Chen et al. · 2020 · Annals of Oncology
100. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
     Charu Aggarwal, Christian D. Rolfo, Geoffrey R. Oxnard, Jhanelle E. Gray, Lynette Marie Sholl, David R. Gandara · 2020 · Nature Reviews Clinical Oncology